+91-98 455 710 46 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
About Us
- Group of Companies
- Subscribe to free learning
NCK services
Course List
Admission
Contact

Home
About Us
- Group of Companies
- Subscribe to free learning
NCK services
Course List
Admission
Contact

Pharma News

Keep updating your pharma knowledge

28 Dec 2014

Indian Biosimilar market valuation

/

Posted Byadmin

/

Comments1

/

Tagsbiocon's biosimilar, DRL biosimilar, indian biosimilar market, leading player in Indian biosimilar market, Lupin biosimilar, market valuation of indian biosimilar, Ranbaxy biosimilar market, Zydus biosimilar launch

Indian biosimilar market is around 2000 Crores.

Related Articles

New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Zydus Cadila and Turkey based Eczacibasi’s strategic collaboration for biosimilar
Learning from Remsima, A Remicade biosimilar
Biocon’s first time ophthalmology molecule, QPI-1007, entered in clinical trial
Serum Institute acquiring Czech vaccine maker Nanotherapeutics Inc. for €72 million

Percentage of Biosimilar market over total pharma market

Biosimilar2.5%

Related Articles

New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Zydus Cadila and Turkey based Eczacibasi’s strategic collaboration for biosimilar
Learning from Remsima, A Remicade biosimilar
Biocon’s first time ophthalmology molecule, QPI-1007, entered in clinical trial
Serum Institute acquiring Czech vaccine maker Nanotherapeutics Inc. for €72 million

Who are the leading players in Indian biosimilar market?

Biocon – Streptokinase, EPO Filgrastim, MAbs
Zydus – Insulin, Streptokinase, Filgrastim
DRL – Rituximab, Filgrastim, Darbepoetin alfa
Lupin – EGFR, Abciximab
Ranbaxy – EPO Filgrastim, Interferon, Infliximab
Wockhardt – Insulin, EPO, Insulin Glargine

Related Articles

New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Zydus Cadila and Turkey based Eczacibasi’s strategic collaboration for biosimilar
Learning from Remsima, A Remicade biosimilar
Biocon’s first time ophthalmology molecule, QPI-1007, entered in clinical trial
Serum Institute acquiring Czech vaccine maker Nanotherapeutics Inc. for €72 million

Torrent’s strategic alliance with Reliance Life Science for biosimilars

Glenmark positive on research molecule GR 17536

About Post Author

admin

1 Response

Rohit

December 29, 2014 at 2:27 pm

Reply

Panacea Biotech, Bharat Biotech also has strong presence.

Leave a Reply Cancel Reply

Save my name, email, and website in this browser for the next time I comment.

The reCAPTCHA verification period has expired. Please reload the page.

pharma business development course

NCK Pharma Solution Private Limited which is conceptualized in Year 2009 with a vision to spearhead innovation in the field of Pharmaceutical, Biotechnology, Medical Devices learning with the technological advances. The mission is to provide "Best On The Go" training services across those industries To Create, Develop, Train tomorrows Industry leaders.

Important URLs

Admission Process
Frequently asked question related to KPE courses
Prospect Identification Process
Verify Course Certificate
Request for Course Completion Certificate

Contact us

General Enquiry / Doubt clarification : info@nckpharma.com

Human Resource : HR@testnckpharma.com

To Escalate any issues: saikatroy@nckpharma.com

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query

First Name

Last Name

Email Address

Phone

Your Query *

Write Here

10 plus 9 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2022-2032 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!